Почетна › Склеродерма › Ilinois
Kliničke studije za Склеродерма u državi Ilinois
9 studija za Склеродерма traži učesnike na lokacijama u državi Ilinois.
Gradovi u državi Ilinois
Zvanični tekst studije (na engleskom)
A Study of AZD0120 in Autoimmune Diseases
- Research Site, Chicago
Тражи се учесникФаза 1/2
Узраст од 18 до 75 · Оба пола · Ажурирано 10. 11. 2026. · NCT07295847A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
Тражи се учесникФаза 1
Узраст од 18 до 74 · Оба пола · Ажурирано 2. 11. 2026. · NCT07085104A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
Тражи се учесникФаза 1
Узраст од 18 до 70 · Оба пола · Ажурирано 26. 10. 2026. · NCT06925542RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
Тражи се учесникФаза 2/3
Узраст од 18 до 75 · Оба пола · Ажурирано 16. 10. 2026. · NCT06328777A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- Northwestern University, Chicago
- The University of Chicago Medical Center, Chicago
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT07497087A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Chicago
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 8. 9. 2026. · NCT05878717Platform Clinical Study for Conquering Scleroderma
- The University of Chicago Medical Center (UCMC), Chicago
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 18. 8. 2026. · NCT06195072AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Willowbrook, Willowbrook
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 31. 7. 2026. · NCT06991114Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Chicago
- aTyr Investigative Site, Chicago
- aTyr Investigative Site, Chicago
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 7. 5. 2025. · NCT05892614Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.